DR4 Antibody | 1139

DR4 Antibody | 1139 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: Anti-DR4 antibody (1139) was raised against a peptide corresponding to 19 amino acids near the carboxy terminus of human DR4.
The immunogen is located within the last 50 amino acids of DR4.

Research Area: Apoptosis

Tested Application: E, WB, IHC-P, ICC, IF

Application: WB: 1 μg/mL; IHC-P: 10 μg/mL; IHC: 10 μg/mL; IF: 20 μg/mL.
Antibody validated: Western Blot in human, mouse and rat samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human and rat samples. All other applications and species not yet tested.

Specificiy: DR4 antibody has no cross reaction to DR5

Positive Control 1: Cat. No. 1202 - A431 Cell Lysate

Positive Control 2: Cat. No. 1203 - A549 Cell Lysate

Positive Control 3: Cat. No. 1224 - Daudi Cell Lysate

Positive Control 4: Cat. No. 10-901 - Human Spleen Tissue Slide

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 50kD
Observed: 55kD (Post-modification: 1 N-linked glycosylation)

Validation:

KO Validation (Figure 1): Anti-DR4 antibodies (1139) specificity was further verified by DR4 specific knockout cell lysate. DR4 signal was detected in wild type cells, but not in the DR4 knockout cells.

Independent Antibody Validation in Cell lines (Figure 2) shows similar DR4 expression profile in human cell lines detected by two independent anti-DR4 antibodies that recognize different epitopes, 1139 against C-terminus domain and 1167 against the N-terminus domain.  DR4 proteins are detected in all the tested cell lines except CaCo-2 at different expression levels by the two independent antibodies. 

KD validation (Figure 7, 10, 11): Anti-DR4 antibody (1139) specificity was further verified by DR4 specific siRNA knockdown. DR4 signal in SW480, Huh7 and HeLa cells transfected with DR4 siRNAs was disrupted in comparison with that in cells transfected with control siRNAs.

Isoform: Human DR4 has only 1 isoform (468aa, 50kD).

Purification: DR4 Antibody is Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: DR4 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: DR4 antibody can be stored at 4μC for three months and -20μC, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: DR4 Antibody: DR4, APO2, CD261, TRAILR1, TRAILR-1, DR4, Tumor necrosis factor receptor superfamily member 10A, Death receptor 4, TRAIL receptor 1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: DR4 Antibody: Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel death domain containing receptor was recently identified and designated DR4 (for death receptor 4). The ligand for this novel death receptor has been identified and termed TRAIL2, 3, which is a new member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates apoptosis and NF-κB activation in many tissues and cells.